{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-21-016940","form_type":"8-K","ticker":"KALA","cik":"0001479419","company_name":"KALA BIO, Inc.","filed_at":"2021-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.698419+00:00","generated_at":"2026-06-27T23:39:56.197574+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Kala Pharmaceuticals promotes Todd Bazemore to President and COO, effective Dec 16, 2021","bullets":["Todd Bazemore, COO since Nov 2017, appointed President and COO effective December 16, 2021.","Mark Iwicki remains CEO and Chairman but no longer serves as President of the Company.","No changes to Bazemore's compensation or compensatory plans in connection with the promotion.","Bazemore has served on Pulmatrix's board of directors since October 2020."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-21-016940","json":"https://secwatch.observer/filing/0001558370-21-016940.json","markdown":"https://secwatch.observer/filing/0001558370-21-016940.md","text":"https://secwatch.observer/filing/0001558370-21-016940.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479419/000155837021016940/0001558370-21-016940-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479419/000155837021016940/kala-20211216x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T23:39:56.197574+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"14ee9be38f","claim":"Mark Iwicki changed role as President at KALA BIO, Inc..","evidence_excerpt":"Mark Iwicki will continue to lead the Company as its Chief Executive Officer and as Chairman of the Board of Directors but will no longer serve as President of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1479419/000155837021016940/0001558370-21-016940-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will no longer serve as"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"220af68074","claim":"Todd Bazemore was appointed as President and Chief Operating Officer at KALA BIO, Inc..","evidence_excerpt":"On December 16, 2021, the Board of Directors of Kala Pharmaceuticals, Inc. (the “Company”) appointed Todd Bazemore, the Company’s Chief Operating Officer, to serve as the Company’s President and Chief Operating Officer, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1479419/000155837021016940/0001558370-21-016940-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}